A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results

@article{Coronel2011ADP,
  title={A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results},
  author={Jaime Coronel and Lucely Cetina and Irlanda Pacheco and C Trejo-Becerril and Aurora Gonz{\'a}lez-Fierro and Erick de la cruz-Hernandez and Enrique P{\'e}rez-C{\'a}rdenas and Luc{\'i}a Taja-Chayeb and Daymi Arias-Bofill and Myrna Candelaria and Silvia Vidal and Alfonso Due{\~n}as-Gonz{\'a}lez},
  journal={Medical Oncology},
  year={2011},
  volume={28},
  pages={540-546}
}
The reversing of epigenetic aberrations using the inhibitors of DNA methylation and histone deacetylases may have therapeutic value in cervical cancer. This is a randomized phase III, placebo-controlled study of hydralazine and valproate (HV) added to cisplatin topotecan in advanced cervical cancer. Patients received hydralazine at 182 mg for rapid, or 83 mg for slow acetylators, and valproate at 30 mg/kg, beginning a week before chemotherapy and continued until disease progression. Response… 
View on Springer
ncbi.nlm.nih.gov
109 Citations
Background Citations
14

109 Citations

Citation Type

Citation Type

Emerging drugs for the treatment of cervical cancer
TLDR
The first Phase III study of bevacizumab, added to standard chemotherapy cisplatin- or non-cisplasin-containing doublet, has shown significant increase in both overall survival and progression-free survival.
a repositioned drug combination for the epigenetic therapy of cancer
New molecular targets against cervical cancer
TLDR
The first Phase III study of bevacizumab, added to cisplatin or a non-cisplatin-containing doublet, showed significant increase in both overall survival and progression-free survival, and further studies are needed before bevazumab plus chemotherapy can be considered the standard of care for advanced disease.
Hydralazine–valproate: a repositioned drug combination for the epigenetic therapy of cancer
TLDR
This combination of hydralazine-valproate and DNMTi with HDACi is being repositioned as an oral DNMT and HDAC inhibitor for cancer epigenetic therapy and is promising but larger studies are needed.
Clinical and biological effects of demethylating agents on solid tumours - A systematic review.
TLDR
Demethylating agents are able to improve clinical outcome and alter methylation status in patients with solid tumours and further research on biomarker predicting therapy efficacy is indicated.
Outcome of Combining Epigenetic Drugs with Other Treatments in the Clinic
TLDR
This chapter discusses the potential of combining epigenetic therapies with current treatment modalities, focusing on either active or completed clinical investigations that have combined epigenetic drugs with existing drugs, exploring better treatment avenues across all diseases.
Developments in the systemic treatment of metastatic cervical cancer.
Epigenetic treatment of solid tumours: a review of clinical trials
TLDR
An overview of the molecular events underlying the antitumour effects of epigenetic treatments is provided and how the proper evaluation of this treatment might result in a better selection of effective agents and in a more rapid development is indicated.
Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer
TLDR
In patients with advanced, persistent, and recurrent cervical cancer, cisplatin-paclitaxel-bevacizumab and topotecan- paclitaxe- bevacIZumab showed the highest efficacy in all regimens investigated in this analysis.
Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype.
TLDR
The administration of dose-adjusted controlled-release hydralazine according to the acetylation status of cancer patients yields similar levels of hydralmethyl, according to their acetylator status.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 45 REFERENCES
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors
TLDR
The clinical benefit noted with the epigenetic agents hydralazine and valproate in this selected patient population progressing to chemotherapy and re-challenged with the same chemotherapy schedule after initiation lends support to the epigenetically-driven tumor-cell chemoresistance hypothesis.
A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer
TLDR
Hydralazine and magnesium valproate produce DNA demethylation, HDAC inhibition, and gene reactivation in primary tumors in breast cancer patients, and appears to increase the efficacy of chemotherapy.
Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC
TLDR
Valproic acid is a clinically relevant HDAC inhibitor, and PBMCs may serve as a surrogate for tumor histone acetylation in solid tumor malignancies and HDAC2 should be further considered as a relevant therapeutic target.
Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers
TLDR
The combination of 5- AZA and valproic acid is safe at doses up to 75 mg/m2 for 5-AZA in patients with advanced malignancies, and a significant decrease in global DNA methylation and induction of histone acetylation were observed.
Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors.
TLDR
Decitabine can be combined safely withcarboplatin at a dose and schedule that causes epigenetic changes equivalent to or greater than that observed in mice with carboplatin-sensitized xenografts.
A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors
TLDR
The combination of 5-AC and phenylbutyrate across three dose schedules was generally well tolerated and safe, yet lacked any real evidence for clinical benefit.
Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes
TLDR
The data show that the 5-azacytidine/VPA combination is active and safe in patients with MDS with a poor prognosis and achievement of VPA therapeutic levels may indeed increase 5-AZA efficacy.
Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas
TLDR
Exposure to various cytotoxic and targeted agents might generate broad pleiotropic resistance by reducing CTR1 and other transporters through methylation-independent mechanisms.
Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial
TLDR
VPA potentiates KTN-induced DNA strand breaks and cytotoxicity and can be combined at 75 mg/kg/d for 5 days with full-dose KTN without overlapping toxicities in metastatic poor prognosis melanoma.
Phase I Trial of Sequential Low-Dose 5-Aza-2′-Deoxycytidine Plus High-Dose Intravenous Bolus Interleukin-2 in Patients with Melanoma or Renal Cell Carcinoma
TLDR
Decitabine can be safely administered with high-dose interleukin 2 and may enhance the activity of IL-2 in melanoma and renal cell cancer, and Objective responses occurred in 31% of melanoma patients.
...
1
2
3
4
5
...